论文部分内容阅读
慢性乙型肝炎(简称慢乙肝)的治疗是较为复杂和困难的,根据国内外的报告,各种疗法对慢乙肝的治疗真正达到痊愈,其比例是不高的。近年来用免疫制剂治疗慢乙肝逐渐增多,获得了一定疗效。目前胸腺素已被公认为人体免疫系统的主宰腺体。胸腺素是由胸腺产生的一簇多肽蛋白质激素,它有促使骨髓中干细胞分化为成熟有细胞免疫活性的T淋巴细胞的功能,认为是一种细胞免疫的促发剂和调整剂。鉴于此,我院于1979年8月起至今,参与了山东省试用胸腺素的临床研究,对27例慢乙肝进行了治疗观察。结果证明,猪胸腺素应用于临床,不仅安全而且具有较好的临床疗效。
Chronic hepatitis B (referred to as chronic hepatitis B) treatment is more complicated and difficult, according to reports at home and abroad, a variety of therapies for the treatment of chronic hepatitis B really up to cure, the proportion is not high. In recent years, immunotherapy with chronic hepatitis B gradually increased, obtained a certain effect. Thymosin is currently recognized as the dominant gland in the body’s immune system. Thymosin is a cluster of peptide protein hormones produced by the thymus. It has the function of differentiating stem cells in bone marrow into mature, immunocompetent T lymphocytes and is considered as a trigger and regulator of cellular immunity. In view of this, our hospital from August 1979 up to now, participated in the trial of clinical trials of thymosin in Shandong Province, 27 cases of chronic hepatitis B were treated. The results show that pig thymosin used in clinical, not only safe but also has good clinical efficacy.